Autopsy report · NCT04300140

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

“Due to business reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year before it started.
• Ran for about 2 years 6 months before it stopped.
• 72 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Aravive, Inc.

Sponsor type

Industry

Conditions

Clear Cell Renal Cell Carcinoma

Interventions

Batiraxcept; Cabozantinib (Cabo); Nivolumab

Participants

72

Sites

17

Countries

United States

Trials that died the same way

• Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
  “Due to financial reasons.” (89% match in meaning)
• A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
  “Due to administrative reasons” (85% match in meaning)
• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (82% match in meaning)
• RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
  “Business reasons.” (82% match in meaning)
• The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients
  “due to organizational reason” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.